Neuropathix, Inc.
NPTX · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $183,477 | $0 | $0 | $0 |
| % Growth | – | -100% | -27.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $183,477 | $0 | $0 | $0 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $0 | $1 | $1 | $0 |
| G&A Expenses | $3 | $3 | $2 | $1 |
| SG&A Expenses | $3 | $3 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $4 | $2 | $1 |
| Operating Income | -$3 | -$4 | -$2 | -$1 |
| % Margin | -0% | – | -1,848.1% | -610.6% |
| Other Income/Exp. Net | $2,940,632 | -$0 | -$1 | $3 |
| Pre-Tax Income | -$4 | -$5 | -$3 | $2 |
| Tax Expense | $0 | $1 | $1 | $1 |
| Net Income | -$4 | -$6 | -$5 | $1 |
| % Margin | -0% | – | -3,622.9% | 538.7% |
| EPS | -0.046 | -0.075 | -0.064 | 0.014 |
| % Growth | 38.9% | -16.4% | -571.3% | – |
| EPS Diluted | -0.046 | -0.075 | -0.064 | 0.014 |
| Weighted Avg Shares Out | 88 | 75 | 71 | 69 |
| Weighted Avg Shares Out Dil | 88 | 75 | 71 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $3 |
| EBITDA | -$3 | -$4 | -$1 | $0 |
| % Margin | -0% | – | -1,070.2% | 23.4% |